RVINE, Calif.--(BUSINESS WIRE)--Cortex Pharmaceuticals, Inc. (AMEX: COR - News), sent two large data packages to the Food & Drug Administration (FDA) today regarding the Company's lead Phase II AMPAKINE? product candidate, CX717. One data set went to the FDA's Division of Neurology Drug Products and the other went to the Division of Psychiatry Products. The original CX717 Investigational New Drug (IND) was filed with Neuropharmacological Division (now Neurology Division) for the treatment of Alzheimer's disease (AD) and the other data package went to the Psychiatry Division, where the Company intends to file a second CX717 IND for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The submitted data package provides clear evidence that the specific histopathological changes seen in animal toxicology studies, which previously caused the FDA to put CX717 on clinical hold, is a postmortem fixation artifact and is not found in the tissue of the animal when it is still living.